Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Optimistic About Catalyst Biosciences Inc (CBIO)

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns, rather than following the ups and downs of equity markets, hoping that they will outperform the broader market. Our research shows that hedge funds do have great stock picking skills, so let’s take a glance at the smart money sentiment towards Catalyst Biosciences Inc (NASDAQ:CBIO).

Is Catalyst Biosciences Inc (NASDAQ:CBIO) a buy, sell, or hold? The smart money is buying. The number of long hedge fund bets went up by 9 recently. Catalyst Biosciences Inc (NASDAQ:CBIO) was in 9 hedge funds’ portfolios at the end of September. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Bovie Medical Corporation (NYSEMKT:BVX), A M Castle and Co (NYSE:CAS), and BIOLASE Inc (NASDAQ:BIOL) to gather more data points.

Follow Catalyst Biosciences Inc. (NASDAQ:CBIO)
Trade (NASDAQ:CBIO) Now!

At the moment there are a multitude of indicators stock traders employ to evaluate publicly traded companies. A pair of the most under-the-radar indicators are hedge fund and insider trading signals. We have shown that, historically, those who follow the best picks of the best investment managers can outpace the market by a very impressive amount (see the details here).

Now, let’s take a glance at the fresh action regarding Catalyst Biosciences Inc (NASDAQ:CBIO).

Hedge fund activity in Catalyst Biosciences Inc (NASDAQ:CBIO)

At the end of the third quarter, 9 elite funds reported a long position in this biotech company, whereas none were holding this stock at the end of the previous quarter. With hedge funds’ sentiment swirling, there exists a select group of key hedge fund managers who were increasing their stakes meaningfully (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Mark Lampert’s Biotechnology Value Fund / BVF Inc has the largest position in Catalyst Biosciences Inc (NASDAQ:CBIO), worth close to $4.8 million, corresponding to 1% of its total 13F portfolio. Sitting at the No. 2 spot is Dov Gertzulin of DG Capital Management, with a $1.2 million position; the fund has 1.4% of its 13F portfolio invested in the stock. Some other professional money managers with similar optimism consist of Stephen DuBois’s Camber Capital Management, D. E. Shaw’s D E Shaw and Alex Denner’s Sarissa Capital Management.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.